These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21524252)

  • 1. Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis.
    Abad C; Waschek JA
    Curr Pharm Des; 2011; 17(10):1025-35. PubMed ID: 21524252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.
    Gonzalez-Rey E; Varela N; Chorny A; Delgado M
    Curr Pharm Des; 2007; 13(11):1113-39. PubMed ID: 17430175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis.
    Baranowska-Bik A; Kochanowski J; Uchman D; Wolinska-Witort E; Kalisz M; Martynska L; Baranowska B; Bik W
    J Neuroimmunol; 2013 Oct; 263(1-2):159-61. PubMed ID: 24041830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the neurological comorbidities of multiple sclerosis: the beneficial effects of VIP and PACAP neuropeptides.
    Jansen MI; Broome ST; Castorina A
    J Integr Neurosci; 2022 Jan; 21(1):33. PubMed ID: 35164469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP.
    Abad C; Gomariz RP; Waschek JA
    Curr Top Med Chem; 2006; 6(2):151-63. PubMed ID: 16454764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VIP, PACAP, and related peptides: from gene to therapy. Proceedings of the 7th International Symposium on VIP, PACAP, and Related Peptides. September 11-14, 2005. Rouen, France.
    Ann N Y Acad Sci; 2006 Jul; 1070():1-628. PubMed ID: 16991209
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.
    Tan YV; Waschek JA
    ASN Neuro; 2011 Oct; 3(4):. PubMed ID: 21895607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.
    Ganea D; Rodriguez R; Delgado M
    Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):127-42. PubMed ID: 12887096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropeptides shaping the central nervous system development: Spatiotemporal actions of VIP and PACAP through complementary signaling pathways.
    Maduna T; Lelievre V
    J Neurosci Res; 2016 Dec; 94(12):1472-1487. PubMed ID: 27717098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory Roles of PACAP and VIP: Lessons from Knockout Mice.
    Abad C; Tan YV
    J Mol Neurosci; 2018 Sep; 66(1):102-113. PubMed ID: 30105629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
    Delgado M; Ganea D
    J Immunol; 2000 Sep; 165(6):3051-7. PubMed ID: 10975815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
    Delgado M; Ganea D
    J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the Pro-Phagocytic and Anti-Inflammatory Functions of PACAP and VIP in Microglia: Implications for Multiple Sclerosis.
    Jansen MI; Thomas Broome S; Castorina A
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
    Delgado M; Jonakait GM; Ganea D
    Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Feb; 164(3):1200-10. PubMed ID: 10640731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
    Delgado M; Reduta A; Sharma V; Ganea D
    J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are multiple sclerosis and amyotrophic lateral sclerosis autoimmune disorders of endogenous vasoactive neuropeptides?
    Staines DR
    Med Hypotheses; 2008; 70(2):413-8. PubMed ID: 17582695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VIP-PACAP system in immunity: new insights for multitarget therapy.
    Gomariz RP; Juarranz Y; Abad C; Arranz A; Leceta J; Martinez C
    Ann N Y Acad Sci; 2006 Jul; 1070():51-74. PubMed ID: 16888149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of serum VIP and PACAP in multiple sclerosis: an exploratory case-control study.
    Al-Keilani MS; Almomani BA; Al-Sawalha NA; Al Qawasmeh M; Jaradat SA
    Neurol Sci; 2022 Apr; 43(4):2621-2630. PubMed ID: 34698942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.